SC
COLL icon

Savant Capital’s Collegium Pharmaceutical COLL Stock Holding History

Savant Capital’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$213K Buy
+5,895
New +$201K ﹤0.01% 1706

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Savant Capital's COLL Position: Q2 2026 in Review

Savant Capital opened a new position in Collegium Pharmaceutical (COLL) in Q2 2026: 5,895 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #1706 among its holdings.

279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Savant Capital held 5,895 shares of Collegium Pharmaceutical worth $213K as of Q2 2026.
  • Collegium Pharmaceutical was a new Savant Capital position in Q2 2026.
  • Collegium Pharmaceutical made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1706 holding.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.